GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Cyclically Adjusted Price-to-FCF

AstraZeneca (AstraZeneca) Cyclically Adjusted Price-to-FCF : 65.23 (As of May. 16, 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Cyclically Adjusted Price-to-FCF?

As of today (2024-05-16), AstraZeneca's current share price is $76.97. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $1.18. AstraZeneca's Cyclically Adjusted Price-to-FCF for today is 65.23.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

AZN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 12.25   Med: 25.08   Max: 73.79
Current: 65.32

During the past years, AstraZeneca's highest Cyclically Adjusted Price-to-FCF was 73.79. The lowest was 12.25. And the median was 25.08.

AZN's Cyclically Adjusted Price-to-FCF is ranked worse than
71.25% of 327 companies
in the Drug Manufacturers industry
Industry Median: 33.34 vs AZN: 65.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.282. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.18 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Price-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.17 48.06 60.81 62.36 57.36

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.90 62.58 58.91 57.36 57.30

Competitive Comparison of AstraZeneca's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AstraZeneca's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=76.97/1.18
=65.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.282/130.0000*130.0000
=0.282

Current CPI (Mar. 2024) = 130.0000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.371 99.800 0.483
201409 0.607 100.000 0.789
201412 0.543 99.900 0.707
201503 -0.453 99.600 -0.591
201506 0.172 100.100 0.223
201509 0.479 100.200 0.621
201512 0.014 100.400 0.018
201603 0.351 100.400 0.454
201606 -0.324 101.000 -0.417
201609 0.176 101.500 0.225
201612 0.521 102.200 0.663
201703 -0.117 102.700 -0.148
201706 -0.032 103.500 -0.040
201709 0.746 104.300 0.930
201712 0.176 105.000 0.218
201803 -0.187 105.100 -0.231
201806 -0.116 105.900 -0.142
201809 0.079 106.600 0.096
201812 0.716 107.100 0.869
201903 -0.452 107.000 -0.549
201906 -0.037 107.900 -0.045
201909 0.290 108.400 0.348
201912 0.377 108.500 0.452
202003 -0.090 108.600 -0.108
202006 0.024 108.800 0.029
202009 0.426 109.200 0.507
202012 0.476 109.400 0.566
202103 0.555 109.700 0.658
202106 0.204 111.400 0.238
202109 0.354 112.400 0.409
202112 0.224 114.700 0.254
202203 0.919 116.500 1.025
202206 0.226 120.500 0.244
202209 0.583 122.300 0.620
202212 0.591 125.300 0.613
202303 0.533 126.800 0.546
202306 0.396 129.400 0.398
202309 0.716 130.100 0.715
202312 0.457 130.000 0.457
202403 0.282 130.000 0.282

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (NAS:AZN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AstraZeneca Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (AstraZeneca) Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (AstraZeneca) Headlines

From GuruFocus